1-1 of 1
Keywords: RAS blockade
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Articles

The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy

Ander Vergara, Carmen Llorens-Cebrià, Nerea Martos, Irene Martínez-Díaz, Frank Stein, Pamela Domínguez-Báez, Mireia Molina-Van den Bosch, Mandy Rettel, Begoña Benito, Sheila Bermejo, Michael Paul Pieper, Conxita Jacobs-Cachá, Maria José Soler
Journal: Clinical Science
Clin Sci (Lond) (2023) 137 (1): 87–104.
https://doi.org/10.1042/CS20220447
Published: 05 January 2023
... proven to delay diabetic kidney disease (DKD) progression on top of the standard of care with the renin–angiotensin system (RAS) blockade. The molecular mechanisms underlying the synergistic effect of SGLT2i and RAS blockers is poorly understood. We gave a SGLT2i (empagliflozin), an angiotensin...
View articletitled, The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy
Open the PDF for The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy in another window
Includes: Supplementary data